Research Progress of HER2 in Cervical Carcinoma
Xinru Yang, Yi Tang, Genyun Liu, Hui Hui, Lin Guo, Na Li, Yun Zhou · 2026
Read Research Progress of HER2 in Cervical Carcinoma by Xinru Yang, Yi Tang, Genyun Liu, Hui Hui, Lin Guo, Na Li, Yun Zhou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13317768.txt.
Description
Xinru Yang and colleagues review, in a 2026 article, the HER2 growth receptor as a target in cervical cancer, where patients with returning or resistant disease run out of options. HER2 drives breast and stomach cancers and is druggable there, but its cervical role is murkier.
Changes in HER2 are uncommon across cervical cancers overall, yet they cluster in glandular subtypes, including HPV-independent forms. The review covers the receptor's biology, how often it appears, what it predicts, and how testing should be standardized. Antibody-drug conjugates, above all trastuzumab deruxtecan, have revived interest by showing activity in HER2-carrying tumors. Careful biomarker selection, the authors argue, will decide which patients truly benefit.
Catalog record
| CREATOR | Xinru Yang, Yi Tang, Genyun Liu, Hui Hui, Lin Guo, Na Li, Yun Zhou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45596 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |